Donafenib vs. lenvatinib combined with transarterial chemoembolization as initial therapy for unresectable hepatocellular carcinoma: a retrospective real-world study
Dona-TACE and LEN-TACE demonstrated comparable efficacy in unresectable HCC, but Dona-TACE exhibited a superior safety profile, suggesting its potential as a preferable option for patients with higher comorbidity risks. Further prospective studies are warranted to validate these findings.
Authors
- Chenghao Zhao (ORCID: https://orcid.org/0000-0001-5392-7529)
- Huzheng Yan (ORCID: https://orcid.org/0000-0002-2196-7734)
- Mingan Li
- Zhanwang Xiang
- Mingsheng Huang (ORCID: https://orcid.org/0000-0003-4749-4231)
- Huan Liu (ORCID: https://orcid.org/0000-0002-0253-647X)
- Mingming Liu (ORCID: https://orcid.org/0000-0002-6750-5068)
- Guohong Li (ORCID: https://orcid.org/0000-0003-0445-5363)
Institutions
- Sun Yat-sen University (CN)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
Publication Details
- Journal
- Quantitative Imaging in Medicine and Surgery
- Published
- 2025-07-21
- DOI
- https://doi.org/10.21037/qims-2025-364
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00